Redmile Group LLC Sells 135,275 Shares of Replimune Group, Inc. (NASDAQ:REPL)

Redmile Group LLC lowered its position in shares of Replimune Group, Inc. (NASDAQ:REPL) by 3.5% during the first quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 3,729,983 shares of the company’s stock after selling 135,275 shares during the period. Redmile Group LLC owned about 6.08% of Replimune Group worth $30,474,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. Price T Rowe Associates Inc. MD grew its holdings in shares of Replimune Group by 12.0% during the first quarter. Price T Rowe Associates Inc. MD now owns 6,548,930 shares of the company’s stock worth $53,505,000 after purchasing an additional 699,679 shares during the last quarter. Fcpm Iii Services B.V. bought a new stake in Replimune Group during the 4th quarter worth approximately $41,024,000. Vanguard Group Inc. increased its position in Replimune Group by 1.2% in the 1st quarter. Vanguard Group Inc. now owns 2,770,328 shares of the company’s stock valued at $22,634,000 after acquiring an additional 32,555 shares during the period. Goldman Sachs Group Inc. increased its position in Replimune Group by 300.3% in the 4th quarter. Goldman Sachs Group Inc. now owns 2,238,883 shares of the company’s stock valued at $18,874,000 after acquiring an additional 1,679,553 shares during the period. Finally, Rafferty Asset Management LLC raised its stake in shares of Replimune Group by 148.1% during the fourth quarter. Rafferty Asset Management LLC now owns 463,397 shares of the company’s stock valued at $3,906,000 after acquiring an additional 276,596 shares during the last quarter. Institutional investors and hedge funds own 92.53% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts recently weighed in on the stock. HC Wainwright boosted their price objective on shares of Replimune Group from $12.00 to $17.00 and gave the stock a “buy” rating in a research note on Friday, June 7th. Barclays increased their price target on Replimune Group from $13.00 to $17.00 and gave the company an “overweight” rating in a research note on Friday, June 7th. Finally, Wedbush reaffirmed an “outperform” rating and issued a $16.00 price objective on shares of Replimune Group in a research note on Thursday, June 6th.

Replimune Group Trading Down 2.8 %

NASDAQ REPL traded down $0.29 during mid-day trading on Monday, reaching $10.06. 503,088 shares of the stock were exchanged, compared to its average volume of 1,250,605. The stock has a market cap of $617.83 million, a P/E ratio of -3.10 and a beta of 1.24. The company has a debt-to-equity ratio of 0.18, a current ratio of 10.72 and a quick ratio of 10.72. Replimune Group, Inc. has a one year low of $4.92 and a one year high of $21.63. The stock has a 50 day simple moving average of $8.18 and a 200-day simple moving average of $7.80.

Replimune Group (NASDAQ:REPL) last posted its quarterly earnings data on Thursday, May 16th. The company reported ($0.82) earnings per share for the quarter, topping the consensus estimate of ($0.86) by $0.04. On average, analysts anticipate that Replimune Group, Inc. will post -3.31 EPS for the current year.

Insider Buying and Selling at Replimune Group

In related news, Chairman Philip Astley-Sparke sold 37,928 shares of the business’s stock in a transaction on Thursday, May 16th. The shares were sold at an average price of $6.47, for a total transaction of $245,394.16. Following the transaction, the chairman now owns 1,487,350 shares in the company, valued at approximately $9,623,154.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other Replimune Group news, Director Robert Coffin sold 11,464 shares of the stock in a transaction that occurred on Thursday, May 16th. The stock was sold at an average price of $6.47, for a total value of $74,172.08. Following the transaction, the director now owns 1,821,872 shares in the company, valued at $11,787,511.84. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Chairman Philip Astley-Sparke sold 37,928 shares of Replimune Group stock in a transaction dated Thursday, May 16th. The shares were sold at an average price of $6.47, for a total transaction of $245,394.16. Following the transaction, the chairman now owns 1,487,350 shares of the company’s stock, valued at $9,623,154.50. The disclosure for this sale can be found here. Over the last three months, insiders have sold 107,598 shares of company stock valued at $712,516. 20.60% of the stock is currently owned by company insiders.

Replimune Group Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.